To Put an End to Misinformation and Medical and Scientific Malpractice Concerning Hydroxychloroquine A Loss of Chance for Patients Faced with SARS-Cov-2

Author(s): Alexis Lacout, Xavier Azalbert, Corinne Reverbel, Gérard Guillaume, Martin Zizi, Christian Perronne

Hydroxychloroquine, initially perceived as a promising treatment for the Covid-19 pandemic, sparked intense debate. Early studies conducted in China and later at the IHU in Marseille under Professor Raoult highlighted its efficacy. A retrospective study involving more than 30,000 patients treated at the IHU fully confirmed its effectiveness. However, the story of this molecule was overshadowed by biased or low-quality studies, where the treatment was often administered too late, at inappropriate and sometimes toxic doses. Despite decades of proven use, the scientific evaluation of hydroxychloroquine resembled sabotage, fueled by conflicts of interest and controversies. Key actors in the crisis, including physicians and prominent media figures in France, played a significant role in its discreditation, often at the expense of a rigorous and objective approach. The saga of this molecule underscores issues that go beyond the medical field, raising questions about the integrity of science and the decisions made during a major health crisis.